As of 18 Sept 2026, 3B Blackbio DX Ltd share price is ₹1,292.85. The stock opened at ₹1,292.85 and had closed at ₹1,296.00 the previous day. Over the last 52 weeks, the stock has recorded a low of ₹1,083.50 and a high of ₹1,750.00. In terms of performance, 3B Blackbio DX Ltd share price has decreased by 0.12% over the past six months and has decreased by 6.09% over the last year.
3BBLACKBIO Stock Price Chart
3B Blackbio DX Ltd Overview
About 3BBLACKBIO
3D Blackbio DX is a leading Indian Biotechnology Company specializing in the Design, Development, Manufacturing, and Commercialization of molecular diagnostic solutions for infectious diseases, oncology, human genetics and antimicrobial resistance. The company provides a comprehensive portfolio of qPCR-based assays, Rapid Tests and NGS-based molecular diagnostic kits for accurate and reliable testing on patient samples.
3B Blackbio DX Ltd Historical Performance
3B Blackbio DX Ltd Fundamentals
3B Blackbio DX Ltd Financials
| Indicator | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Revenue | 111.44 | 105.56 | 83.04 | 66.60 | 25.61 |
| EBITDA | 67.34 | 64.89 | 47.42 | 36.84 | 8.86 |
| Net Profit | 49.32 | 47.56 | 34.21 | 26.42 | 8.01 |
| EPS | 57.56 | 55.51 | 39.93 | 35.27 | 10.67 |
3B Blackbio DX Ltd Technical Analysis
| Indicator | Value |
|---|---|
| Support 1 (S1) | 1,268.72 |
| Resistance 1 (R1) | 1,344.67 |
| Pivot Point | 1,317.38 |
3B Blackbio DX Ltd Dividend History
| Ex Date | Dividends Date | Record Date | Dividend Type | Dividend Details |
|---|---|---|---|---|
| 19-Sep-2025 | 28-May-2025 | 19-Sep-2025 | Final | ₹4.00 |
| 17-Sep-2024 | 29-May-2024 | 18-Sep-2024 | Final | ₹3.00 |
| 15-Sep-2023 | 29-May-2023 | 15-Sep-2023 | Final | ₹2.50 |
| 14-Sep-2022 | 27-May-2022 | 16-Sep-2022 | Final | ₹2.50 |
| 14-Sep-2021 | 23-Jun-2021 | 16-Sep-2021 | Final | ₹1.00 |
3BBLACKBIO Key Leadership Details
Last Updated: Mar 2025
| Name | Position |
|---|---|
| D K Dubey | Chairman |
| N K Dubey | Chief Financial Officer |
| Mithala Dubey | Non Executive Director |
3B Blackbio DX Ltd Peer Comparison
| Company | Price | M.Cap (Cr) | P/E (TTM) | ROE (TTM) |
|---|---|---|---|---|
| Apollo Hospitals Enterprise LtdAPOLLOHOSP | ₹8,764.50+0.78% | ₹1,10,231.07 | 59.08 | 20.48% |
| Max Healthcare Institute LtdMAXHEALTH | ₹1,040.10+1.47% | ₹1,02,534.79 | 72.27 | 13.42% |
| Fortis Healthcare LtdFORTIS | ₹889.80+2.24% | ₹68,746.49 | 70.10 | 10.53% |
Disclaimer
The information provided on this page is for informational purposes only and should not be construed as investment advice, recommendation, or solicitation to buy or sell any securities or financial pr...
Frequently Asked Questions
- The share price of 3B Blackbio DX Ltd today is ₹1,292.85 on NSE and ₹1,292.85 on BSE.
- The 52-week high of 3B Blackbio DX Ltd is ₹1,750.00, while the 52-week low is ₹1,083.50.
- The current market capitalisation of 3B Blackbio DX Ltd is approximately ₹1,112 crore.
- The P/E (Price-to-Earnings) ratio of 3B Blackbio DX Ltd is 18.03. The ratio may vary with changes in the share price and earnings.
- The P/B (Price-to-Book) ratio of 3B Blackbio DX Ltd is 3.52. It compares the company’s market value with its book value and can provide an indication of how the market values the company relative to its net assets.
- To buy 3B Blackbio DX Ltd shares, you first need to open a demat account before you can place an order. Here's the process:
• Open a demat account online using your PAN, Aadhaar and bank details.
• Add funds to your trading account via UPI or net banking.
• Search for 3BBLACKBIO on TradeMobi or the Anand Rathi web platform.
• Place your order
• Track your holdings in the portfolio section. - Over the past 3 years, 3B Blackbio DX Ltd has delivered a return of approximately 65.56%. This return is based on the change in the share price over the specified period and may differ depending on the measurement date. Past performance does not guarantee future returns.
- The shareholding pattern of 3B Blackbio DX Ltd comprises different categories of shareholders. As of Jun 2026, the shareholding is approximately 40.95% promoters, 2.50% FIIs, 2.15% DIIs, and 37.05% public shareholders.

